Loading stock data…
Evommune (EVMN)
$15.05-10.13 (-40.23%)
After Hours$15.01-0.04 (-0.26%)· Last close Jun 29
Evommune, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $10.00M | — | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.95M↑ | -$29.72M↓ | -$13.33M | — | -$21.45M |
| Net Income | -$21.67M↑ | -$28.27M↓ | -$12.47M | — | -$20.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneou...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$720.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.30%
Volume
Today's trading volume
10.42M
Recent News
Evommune terminates oral drug’s development in CSU
While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
Evommune, Inc. (NYSE:EVMN) shares dropped 17% on Monday after the company announced that its Phase 2b study of EVO756 in chronic spontaneous urticaria (CSU) failed to achieve its primary efficacy endpoint.
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...